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Abstract
22q11.2 Deletion Syndrome (22q11.2DS) is associated with high risk of psychiatric disorders and cognitive impairment.
It remains unclear to what extent key cognitive skills are associated with psychopathology, and whether cognition is
stable over time in 22q11.2DS. 236 children, adolescents and adults with 22q11.2DS and 106 typically developing
controls were recruited from three sites across Europe. Measures of IQ, processing speed, sustained attention, spatial
working memory and psychiatric assessments were completed. Cognitive performance in individuals was calculated
relative to controls in different age groups (children (6–9 years), adolescents (10–17 years), adults (18+ years)).
Individuals with 22q11.2DS exhibited cognitive impairment and higher rates of psychiatric disorders compared to
typically developing controls. Presence of Autism Spectrum Disorder symptoms was associated with greater deﬁcits in
processing speed, sustained attention and working memory in adolescents but not children. Attention deﬁcit
hyperactivity disorder in children and adolescents and psychotic disorder in adulthood was associated with sustained
attention impairment. Processing speed and working memory were more impaired in children and adults with
22q11.2DS respectively, whereas the deﬁcit in sustained attention was present from childhood and remained static
over developmental stages. Psychopathology was associated with cognitive proﬁle of individuals with 22q11.2DS in an
age-speciﬁc and domain-speciﬁc manner. Furthermore, magnitude of cognitive impairment differed by
developmental stage in 22q11.2DS and the pattern differed by domain.
Introduction
22q11.2 Deletion syndrome (22q11.2DS) is associated
with a range of psychiatric disorders, with over half of
individuals reaching criteria for at least one psychiatric
diagnosis across the lifespan1,2. Most strikingly, in adult
samples, ~40% are diagnosed with a psychotic disorder
including schizophrenia3,4, although it must be noted that
this may reﬂect ascertainment bias as more recent
population estimates are much lower5. Several studies
have established a high prevalence of childhood psycho-
pathology manifesting as attention deﬁcit hyperactivity
disorder (ADHD), autism spectrum disorder (ASD) and
anxiety disorders2,3. Prevalence of psychiatric disorders
appears to follow different trajectories over the lifespan,
such as the rate of anxiety disorders remaining relatively
stable across developmental stages6, whereas the rate of
ADHD diagnosis declines, with 33–43% individuals no
longer reaching diagnostic criteria at follow-up in ado-
lescence7,8. Therefore, it is important to take a develop-
mental perspective when considering psychiatric
disorders in 22q11.2DS, which reﬂects the dynamic
development of the brain.
22q11.2DS is highly penetrant for a broad range of
cognitive impairments6,9,10. It is important to investigate
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whether the cognitive deﬁcits in 22q11.2DS are stable
over development, or if they are worse at certain devel-
opmental time points, as looking at cognition across the
life span in a high-risk group for psychopathology can
provide important insights into underlying mechanisms11.
Studies investigating associations between cognition
and psychopathology in young people with 22q11.2DS
have produced mixed results. Some previous research has
suggested that cognitive deﬁcits and psychopathology
constitute distinct pleiotropic outcomes of the dele-
tion2,12. Other research has suggested that cognition may
mediate psychopathology, for example, that deﬁcits in
executive functioning may index vulnerability to ASD or
ADHD in children with 22q11.2DS13. Conversely, reverse
causation has been proposed, with the ﬁndings that pre-
sence of anxiety symptoms may mediate the relationship
between 22q11.2DS and working memory capacity, with
greater anxiety linked to less efﬁcient cognitive perfor-
mance14. Other research has reported that the presence of
ASD or ADHD may predict poorer executive functioning
in 22q11.2DS15. It has furthermore been suggested that
age may play a role in these complex relationships
between cognitive deﬁcits and psychopathology13. To
date, we are not aware of any papers in 22q11.2DS
reporting on associations in cognition and psycho-
pathology across developmental stages (i.e., children and
adolescents), which has been proposed as an important
topic for future research13.
Research on the relationship between cognition and
psychopathology in adults with 22q11.2DS has largely
focused on associations with psychotic disorders. Indivi-
duals with 22q11.2DS and schizophrenia have been
reported to display greater deﬁcits on measures of
executive function such as working memory and sus-
tained attention than individuals with 22q11.2DS without
schizophrenia16–18, conforming to studies of schizo-
phrenia in individuals without a genetic syndrome19.
Additionally, longitudinal studies following adolescents
with 22q11.2DS into adulthood found that IQ (particu-
larly verbal IQ) was lower in those with psychotic dis-
orders than those without psychotic disorder6,20. A cross-
sectional study of adults found deﬁcits in verbal learning,
social cognition and set-shifting between adults with
22q11.2DS and schizophrenia compared to those without
schizophrenia, but did not ﬁnd this difference on atten-
tional measures, suggesting that attentional dysfunction
may be a general feature of 22q11.2DS over and above the
inﬂuence of psychosis21. Despite this, inattention symp-
toms have been proposed to have an important role in
psychosis in 22q11.2DS22. Therefore, there is still debate
as to which cognitive functions are associated with psy-
chotic disorders in 22q11.2DS.
The literature on cognitive trajectories from childhood
to adulthood in 22q11.2DS is also inconsistent. Some
studies have reported evidence of cognitive decline as
individuals get older, with studies focussing on IQ
reporting negative associations with age both cross-
sectionally12 and longitudinally23. Other longitudinal
studies comparing children with the deletion with a
comparison sample of typically developing siblings
assessed with the same measures have not found evidence
of cognitive decline for IQ or a range of neurocognitive
functions that have been associated with psychiatric dis-
order, including processing speed, sustained attention and
working memory9,24, although there may be develop-
mental lags in speciﬁc domains (i.e., children with
22q11.2DS lag behind controls without the deletion).
Furthermore, it has been reported that longitudinal cog-
nitive proﬁles were similar between children with
22q11.2DS and IQ-matched and age-matched children
with idiopathic intellectual disabilities (IID; Van Den
Heuvel25). Examining impairments in speciﬁc cognitive
domains such as attention may provide insights into
neurobiological processes11 and that these functions may
be more sensitive both to cognitive change and to reme-
diation strategies than a global measure of intelligence like
IQ26.
The majority of the studies of speciﬁc cognitive domains
in 22q11.2DS have focussed on children and adolescents
although it is recognised that many cognitive functions
continue to mature through early adulthood27,28. Our
understanding of cognitive function in adults with the
deletion thus remains limited29–31. One study found that
adults with 22q11.2DS exhibited deﬁcits in visuopercep-
tual, planning, abstract, and social cognition compared to
age-matched, gender-matched, and IQ-matched controls,
which further reinforces the importance of considering
speciﬁc cognitive domains beyond a sole focus on IQ32.
When examining change over a wider age range up to 26
years, one study found that overall working memory tra-
jectory in 22q11.2DS differed from typically developing
controls whereas other domains such as inhibition fol-
lowed the same developmental course28. It was therefore
proposed that individuals with 22q11.2DS may reach a
“developmental plateau” in working memory ability
before controls, but this was only observable because of
the inclusion of older adolescents and adults28. However,
another study with a similar age range investigating
working memory abilities found that individuals with
22q11.2DS caught up with controls by age 2526. A recent
meta-analysis of cognitive functioning in 22q11.2DS
compared to controls reported that in paediatric samples
there was evidence for greater cognitive impairment in
older children, but in adulthood there was an improve-
ment in cognitive abilities over time31, highlighting the
importance of looking over a wide age range to under-
stand better the continuing development of cognitive
functions in 22q11.2DS. Furthermore, it is a general
Morrison et al. Translational Psychiatry           (2020) 10:53 Page 2 of 11
methodological limitation of previous research that dif-
ferent studies with relatively small numbers of partici-
pants have used different cognitive testing batteries,
limiting comparisons that can be made across samples31.
There is a need for testing a range of cognitive domains in
a large sample where all participants have completed the
same battery17.
This study took a developmental approach with a con-
sistent cognitive battery across international sites with the
primary aim to examine associations between cognitive
performance and psychopathology. Speciﬁcally, in young
individuals with 22q11.2DS we investigated whether any
links with cognitive performance and the presence of
ASD, ADHD or anxiety disorders differed for children
and adolescents. In adults, we examined the association of
cognition with the presence of a psychotic disorder. Based
on the majority of previous research, we hypothesised that
presence of a psychiatric disorder would be associated
with greater cognitive deﬁcits. The second aim was to
assess whether cognitive functioning differed across the
three developmental stages in 22q11.2DS (childhood,
adolescence, and adulthood) compared to typically
developing individuals. Previous research suggests that we
may expect greater cognitive impairments in older indi-
viduals compared to younger individuals, at least in some
domains.
Methods
Participants
Three hundred and forty-two participants (236 indivi-
duals with 22q11.2DS and 106 controls) were recruited
from three sites across Europe (see Supplementary Table
1). Cardiff University recruited children and adolescents
with 22q11.2DS and their typically developing control
siblings, and adults with 22q11.2DS through the Experi-
ences of CHildren with cOpy number variants (ECHO)
and Deﬁning Endophenotypes From Integrated Neu-
roscience (DEFINE) studies. KU Leuven recruited ado-
lescents and adults with 22q11.2DS and Maastricht
University recruited adults with 22q11.2DS and adult
community controls. Participants were ascertained
through similar recruitment methods, which was not on
the basis of psychiatric presentation but largely through
medical genetics services after receiving a diagnosis of
22q11.2DS (see Supplementary Table 1 for further
details). Children were deﬁned as 6–9.9 years old, ado-
lescents as 10–17.9 years old and adults 18+ following
World Health Organisation guidelines33. Mean ages were
comparable in 22q11.2DS and control groups within the
adolescent and adult developmental stages; however, in
the child stage the 22q11.2DS group were on average a
few months younger (see Supplementary Table 2). Gender
distributions were comparable in the child and adolescent
developmental stages but there were signiﬁcantly more
female participants in the adult stage (see Supplementary
Table 2).
Fifty-four participants (1 child, 3 adolescents and 50
adults) were taking neuroactive and/or thyroid medica-
tion at the time of testing (see Supplementary Table 3 for
further details). The authors assert that all procedures
contributing to this work comply with the ethical stan-
dards of the relevant national and institutional commit-
tees on human experimentation and with the Helsinki
Declaration of 1975, as revised in 2008. Written informed
consent was gained from primary carers and participants.
The study was approved by ethics committees at the three
sites (Cardiff, NHS Wales Research Ethics Committee;
Maastricht, Maastricht University Medical Centre; KU
Leuven; Research Medical Ethics Committee UZ KU
Leuven).
Cognitive assessments
A battery of three neurocognitive tasks comparable
across sites was administered using Cambridge Neu-
ropsychological Test Automated Battery (CANTAB)
software34. Given the high risk of neurodevelopmental
disorders in 22q11.2DS, cognitive tests were chosen that
would be sensitive to deﬁcits associated with these dis-
orders (ADHD35, autism36, schizophrenia37). These mea-
sured processing speed, sustained attention and spatial
working memory (see Supplementary Table 4 for full task
details). CANTAB raw scores were transformed into age-
standardised z-scores based on normative data. Full scale
IQ (FSIQ), verbal IQ (VIQ), and performance IQ (PIQ)
were assessed at each site with Wechsler scales in vali-
dated local language versions (see Supplementary Table 5
for full details). IQ scores were calculated by standardising
raw scores for age based on normative data. Not all par-
ticipants completed all cognitive tasks, due to cognitive or
behavioural issues or time constraints, but all completed
at least one; this is detailed in Table 1.
Psychiatric assessments
Details of the psychiatric assessment of children and
adolescents have been previously reported2; for further
details see Supplementary Table 5. Assessment details
for adult participants are also reported in Supplemen-
tary Table 5. Instruments were comparable across sites
and provided DSM-IV diagnoses of psychiatric dis-
orders including schizophrenia, schizoaffective disorder
and psychotic disorder. Diagnoses at each of the three
sites were made during consensus meetings led by a
psychiatrist. All three centres that have contributed data
to this paper are part of the International 22q11.2
Deletion Syndrome Brain Behaviour Consortium
(IBBC), which used careful evaluation procedures to
ensure phenotypic harmonisation across sites (descri-
bed in detail in the ref. 38).
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Analysis
Mean neurocognitive z-scores and IQ scores were
compared between individuals with 22q11.2DS and the
control sample in the separate developmental stages.
Children and adolescents were compared against sibling
controls with ANOVA with covariate for relatedness, and
adults were compared against community controls with t-
tests (with correction for unequal variance if applicable).
Mean FSIQ, VIQ, and PIQ scores were compared
between sibling and community controls with t-tests
(with correction for unequal variance if applicable) to
investigate whether these different groups of typically
developing individuals performed differently.
Within each developmental stage the mean score for the
control sample (typically developing siblings for the
children and adolescents and community controls for the
adults) was subtracted from the score of each individual
with 22q11.2DS for each cognitive measure. This pro-
duced a difference score for each individual with
22q11.2DS on each measure. A difference of 0 would
therefore represent no difference between the individual
with 22q11.2DS and the control mean and a negative
difference would represent an impairment on that mea-
sure in the individual with 22q11.2DS compared to the
mean control performance. This enabled the analysis to
take into account control performance while comparing
performance across age groups (i.e., it enabled us to focus
on variation in cognitive performance that can be attrib-
uted to the 22q11.2 deletion).
Aim 1: associations of cognition and psychopathology in
the three developmental stages in 22q11.2DS
No children or adolescents met criteria for psychotic
disorder at the time of assessment. One adolescent had
been diagnosed with a psychotic disorder in the past
which was currently managed with antipsychotic medi-
cation. Two other adolescents and one child were taking
medication, which could have affected cognitive perfor-
mance (see Supplementary Table 3), so sensitivity ana-
lyses were run for each analysis these four participants
were included in. 2/60 children and 8/64 adolescents with
22q11.2DS reported subthreshold psychotic phenomena.
As these numbers were small, comparisons in cognition
between those with and without psychotic disorder/
experiences would not have been reliable. However, we
included psychotic experiences as a covariate in analyses
to establish whether this altered results.
Chi-square tests were conducted to establish whether
prevalence of probable ASD, ADHD or anxiety disorder
differed in children and adolescents with 22q11.2DS
compared to their typically developing siblings.
To investigate whether childhood psychopathology was
associated with greater cognitive impairment in childhood
or adolescence 2 × 2 ANOVAS were conducted to test forTa
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interaction effects (i.e., child vs. adolescent × diagnosis
present or absent) and main effects of psychopathology
(i.e., diagnosis present or absent).
To compare performance on cognitive measures
between adults with psychotic disorder and those without,
independent t-tests were performed either with or with-
out a correction for unequal variance, as applicable.
Aim 2: comparing cognitive performance across the three
developmental stages in 22q11.2DS
To compare performance on cognitive measures across
the three developmental stages, one-way ANOVAs were
performed on the difference scores for each cognitive
measure. If a signiﬁcant overall group difference (p-value <
0.05) was found, Tukey HSD post hoc tests were con-
ducted to establish which developmental stages differed
from each other.
Data analysis was conducted using R version 3.5.0. For
code availability please contact the ﬁrst author. All analyses
were also conducted with site as a covariate to control for
differences across sites, such as assessment measures.
Statistical correction
The Benjamini-Hochberg method for controlling False
Discovery Rate (FDR) was used to correct for multiple
comparisons39. This method ranks p-values in a cluster of
tests, then divides the rank by the number of tests in the
cluster, then multiplying by an acceptable FDR (in this
case, 10%, following Crawford40) to produce a Benjamini-
Hochberg critical value. If the original p-value is below the
Benjamini-Hochberg critical value, then it survives FDR
correction.
Results
Individuals with 22q11.2DS in every developmental
stage showed impairment on all neurocognitive and IQ
scores compared to controls except for adolescents in
processing speed (Table 1). All comparisons survived FDR
correction. There was no difference between sibling and
community controls in FSIQ (p= 0.322), VIQ (p= 0.841)
or PIQ (p= 0.318).
Aim 1: associations of cognition and psychopathology in
the three developmental stages in 22q11.2DS
Children and adolescents
Children with 22q11.2DS had higher rates of probable
ASD, ADHD, and anxiety disorders compared to their
typically developing siblings (Supplementary Table 6).
Adolescents with 22q11.2DS had higher rates of probable
ASD and ADHD compared to their typically developing
siblings (Supplementary Table 6). Cognitive difference
scores for children and adolescents with 22q11.2DS with
or without probable ASD, ADHD, or anxiety disorder are
displayed in Supplementary Tables 7–9, respectively.
Probable ASD
Interaction effects between probable ASD status and
developmental stage were present on all neurocognitive
measures (Table 2). Adolescents with probable ASD
appeared to display a greater deﬁcit in these domains
compared to adolescents without ASD, but this did not
appear to be the case for children (Supplementary Table
7; Supplementary Fig. 1). There were no interaction
effects between probable ASD status and developmental
stage on IQ measures (Table 2). There were no main
effects of probable ASD on IQ measures. Most compar-
isons survived FDR correction (Table 2).
ADHD
There were no interaction effects between ADHD status
and developmental stage on neurocognitive or IQ mea-
sures (Table 2). There was a main effect of ADHD on
sustained attention such that those with ADHD displayed
greater impairment regardless of developmental stage
(Supplementary Table 8; Supplementary Fig. 2). This
survived FDR correction. There were no associations
between ADHD and processing speed, working memory
or IQ measures.
Anxiety disorder
There were no interaction effects between anxiety dis-
order status and developmental stage or main effects of
anxiety disorder status on neurocognitive or IQ measures
(Table 2 and Supplementary Table 9).
Sensitivity analyses excluding four participants taking
medication which could have affected cognitive perfor-
mance did not affect results. Furthermore, analyses
including presence of subthreshold psychotic experiences
as a covariate did not alter results. Additionally, as most of
the child and adolescent participants were recruited from
the Cardiff site, sensitivity analyses were conducted
removing the 5 Leuven adolescents and results were
unchanged, suggesting site did not affect performance.
Adults
Sixteen percent of the adult sample (n= 18) were
categorised as having a psychotic disorder; 14 of these had
a schizophrenia diagnosis, three a diagnosis of psychotic
disorder not otherwise speciﬁed (NOS), and one a diag-
nosis of schizoaffective disorder. None of the control
group were diagnosed with a psychotic disorder.
Seven percent of adults without psychotic disorder (n=
6) met criteria for prodromal psychotic symptoms. As this
was a small number of adults, it was not appropriate to
categorise these as a separate group, and so they were
classiﬁed as adults without psychotic disorder. A sensi-
tivity analysis including presence of prodromal symptoms
as a covariate did not change results.
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Cognitive difference scores for adults with 22q11.2DS
with or without psychotic disorder are displayed in Sup-
plementary Table 10.
Individuals with a psychotic disorder displayed greater
impairment in sustained attention and all IQ measures
(Table 3 and Supplementary Figs. 3, 4). Conversely, pre-
sence of a psychotic disorder was not associated with
processing speed or working memory. All comparisons
survived FDR correction.
The association between IQ and sustained attention in
adults with 22q11.2DS and psychotic disorder was non-
signiﬁcant (Pearson correlation r= 0.32, p= 0.344), sug-
gesting that these domains have distinct associations with
psychosis.
Fifty adult participants were taking medication which
could have affected cognitive performance. As this was a
large proportion of the sample, a sensitivity analyses would
not have been appropriate, so analyses were repeated con-
trolling for medication as a covariate. Results were
unchanged. Additionally, as the adult participants were
recruited from three different sites, analyses were conducted
with site included as a covariate and results were unchanged.
Aim 2: comparing cognitive performance across
developmental stages in 22q11.2DS
Cognitive difference scores across developmental stages
are displayed in Supplementary Table 11. Working
memory performance differed across the developmental
stages (Table 4). Post hoc tests revealed that adults with
22q11.2DS showed more impairment on this task than
children and adolescents. Processing speed differed
according to developmental stage with children displaying
greater deﬁcits than adults. Impairment in sustained
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Table 3 Association of cognition and psychotic disorder
in adults with 22q11.2DS relative to typically developing
controls.
Psychotic disorder
t (df) p Effect size; Cohen’s d
Neurocognitive scores
Processing speed 0.61 (97) 0.54 0.17
Sustained attention 3.13 (12.67) 0.008 1.29
Working memory 0.26 (104) 0.797 0.07
IQ test scores
Full-scale IQ 2.43 (102) 0.017 0.66
Verbal IQ 2.64 (100) 0.010 0.74
Performance IQ 2.03 (100) 0.045 0.57
p values that are statistically signiﬁcant are shown in bold.
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attention appeared to be similar across developmental
stages (Supplementary Fig. 5).
There were differences across developmental stages on
all measures of IQ (Table 4). Post hoc tests revealed that
adults showed greater impairment than adolescents on all
measures, and that adults also performed worse than
children on PIQ (Supplementary Fig. 6). All comparisons
survived FDR correction.
Fifty-four participants were taking medication which
could have affected cognitive performance, so analyses
were repeated controlling for medication as a covariate.
Results were unchanged. When controlling for site as a
covariate, results were largely unchanged except there was
a signiﬁcant difference between children and adolescents
on working memory which was previously not signiﬁcant.
All analyses were also ran controlling for gender as a
covariate, as it has been previously reported that there
may be gender differences in cognitive performance15 but
this did not change any associations.
Discussion
To our knowledge, this is the largest study in 22q11.2DS
where all participants have completed the same testing
battery in the speciﬁc cognitive domains of processing
speed, sustained attention and working memory, in addition
to standard IQ assessments. Furthermore, typically devel-
oping individuals (siblings and community controls) were
included to account for natural variation in cognition over
development. Presence of psychopathology had develop-
mental and domain speciﬁc associations with the cognitive
proﬁle. The presence of probable ASD, ADHD, and psy-
chotic disorder at speciﬁc developmental stages were dif-
ferentially associated with deﬁcits on speciﬁc cognitive
domains, suggesting there may be shared brain pathways or
potential critical periods for cognitive development.
Cognitive impairments were present across childhood,
adolescence, and adulthood in 22q11.2DS compared to
typically developing controls, but magnitude of impair-
ment differed by developmental stage and the pattern
differed by domain. Processing speed and working
memory were more impaired in children and adults with
22q11.2DS respectively, whereas the deﬁcit in sustained
attention was present at the same magnitude across all
developmental stages. Impairments in working memory
and IQ were more salient in adults with 22q11.2DS than
children and adolescents.
Rates of probable ASD, ADHD, and anxiety disorder in
the current study were comparable to a large previous
study of individuals with 22q11.2DS3. Presence of prob-
able ASD was found to interact with developmental stage
such that adolescents with probable ASD experienced
greater impairment than children with probable ASD in
processing speed, sustained attention and working
memory. Previous research including a subgroup of par-
ticipants from the current study did not ﬁnd a relationship
between probable ASD and cognitive function2 (see
Supplementary Table 1). This previous study, however,
considered children and adolescents as one group,
whereas in the current study the increased sample size
enabled comparison between the developmental stages of
childhood and adolescence, allowing a developmental
perspective on the relationship between ASD and
cognition.
These results could imply that cognitive impairment
associated with ASD emerges in adolescence and is not
present in early childhood. This indicates that there may
be a sensitive period for acquiring certain cognitive
domains in ASD, whereby individuals with ASD acquire
skills well in childhood but this does not continue into
adolescence, a theory which is in line with longitudinal
Table 4 Comparison of associations between developmental stage and cognitive impairment between the three
developmental groups.
ANOVA Tukey HSD post-hoc tests
F (df) p Effect size; ηp
2 Child and adolescent Child and adult Adolescent and adult
Neurocognitive scores
Processing speed 3.32 (2,211) 0.038 0.031 0.080 0.045 0.999
Sustained attention 0.82 (2,188) 0.443 0.009 – – –
Working memory 20.39 (2,228) <0.001 0.152 0.051a 0.002 <0.001
IQ test scores
Full-scale IQ 5.74 (2,224) 0.004 0.049 0.20 0.644 0.003
Verbal IQ 3.81 (2,222) 0.024 0.033 0.089 0.975 0.025
Performance IQ 13.02 (2,224) <0.001 0.104 0.936 <0.001 <0.001
aWhen controlling for site as a covariate, this difference was signiﬁcant (p= 0.028).
p values that are statistically signiﬁcant are shown in bold.
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studies of young people with autism41. It is unclear from
this cross-sectional study design whether our ﬁndings
indicate a developmental lag, where the gap between
children and adolescents with ASD increases with age
compared to those without ASD, or whether adolescents
with ASD are performing worse at a later time point than
at baseline, which would index cognitive deterioration
(see Chawner24). Longitudinal research is vital to make
this distinction.
It could also be possible that increasing perceived social
and academic demands on individuals with ASD during
adolescence result in greater difﬁculty reaching equivalent
mental age to controls than in childhood41. Alternatively,
it has been proposed that measuring ASD symptoms in
young people with 22q11.2DS may be indexing pre-
psychotic traits, especially social deﬁcits that are mea-
sured by the SCQ42. As the presence of such prodromal
symptoms has been associated with poorer cognitive
functioning in 22q11.2DS26,28, an alternative explanation
for the association in this study of probable ASD with
cognitive deﬁcits in adolescence could be that those
categorised with probable ASD are actually manifesting
prodromal psychotic symptoms. However, including the
presence of subthreshold psychotic experiences as a
covariate did not change results. Furthermore, a long-
itudinal study did not ﬁnd an association between autistic
features in individuals with 22q11.2DS in childhood and
their risk of developing psychotic disorders or symp-
toms43 which suggests that both psychiatric conditions
may be pleiotropic phenotypes of 22q11.2DS.
However, as the presence of probable ASD was deter-
mined by the SCQ which is a screening questionnaire and
does not provide a formal research diagnosis, caution
must be taken in interpreting these ﬁndings. This is a
questionnaire which was developed to align to the gold-
standard Autism Diagnostic Interview-Revised (ADI-R;
Lord, Rutter and Le Couteur44) and the two measures
correlate highly (Berument, Rutter, Lord, Pickles and
Bailey45; Charman46). However, it is thought that it does
not perform as well as the ADI-R when discriminating
ASD from intellectual disability (ID; Berument, Rutter,
Lord, Pickles and Bailey45) so it is possible that the SCQ
may be indexing more than ASD only. However, there
was no association of IQ with meeting the cut-off for ASD
on the SCQ, which suggests the SCQ was not just
indexing ID. Furthermore, this criteria has been applied in
previous research studies2,47. Above all, the ﬁnding that
children who meet clinical cut-off for social commu-
nicative deﬁcits may have different cognitive trajectories is
interesting.
Presence of ADHD in childhood or adolescence was
associated with a greater deﬁcit on the sustained attention
task but no other cognitive measure, which is in agree-
ment with previous ﬁndings13. As processing speed and
working memory were not associated with presence of
ADHD, this lends support to the hypothesis that there
may be a speciﬁc neurobiological pathway which leads to
attention deﬁcits which affect cognition and behaviour13.
It should be noted that the clinical presentation of ADHD
in 22q11.2DS differs from idiopathic ADHD in that it is
predominantly the inattentive subtype48, so differing
relationships with cognition may be seen in other sub-
types. In a previous study including a subgroup of parti-
cipants from the current study (see Supplementary Table
1), there was no relationship between ADHD and cogni-
tive function2. Possibly the larger sample size in the cur-
rent study enabled detection of the association between
sustained attention and ADHD due to increased statistical
power. The presence of anxiety disorder, however, was
not associated with cognitive function in either the cur-
rent or previous study including some of the same par-
ticipants2, providing further suggestion that these traits
may not be linked in 22q11.2DS. Other research which
found a relationship between anxiety and working mem-
ory impairments14 controlled for ADHD as a covariate in
the analysis, which may explain different ﬁndings.
Adults with 22q11.2DS and psychotic disorder appeared
to show greater deﬁcits in attention as has been previously
reported16. Furthermore, the fact that impairment in
attention was present in the sample from a young age and
was associated with psychosis supports the hypothesis
that attention deﬁcits are a core feature of schizophrenia,
both in the high-risk and clinical stages22. There were
greater deﬁcits in IQ compared to those with no psychotic
disorder, which is in line with previous research sug-
gesting that a decline in IQ precedes the emergence of
psychotic disorder6,20. However, as this study is cross-
sectional it cannot be determined if the cognitive
impairments precede or result from the onset of psy-
chosis. We did not ﬁnd deﬁcits in working memory or
processing speed which have been previously reported in
individuals with 22q11.2DS and psychotic disorder16. It
could be that in our sample these deﬁcits were general
features of 22q11.2DS and not associated with psy-
chosis21. Furthermore, in previous studies attention and
working memory have been combined into a broader
“executive function” domain which was reported as the
most striking impairment in individuals with 22q11.2DS
and psychosis;17 however, as we have shown, there may be
differences even within this broad executive function
domain, with deﬁcits in attention possibly driving the
association with psychotic disorder.
Overall, children with 22q11.2DS displayed a greater
deﬁcit in processing speed compared to adults. This
supports previous longitudinal research showing that
there is developmental maturation in the processing speed
domain through adolescence24 and it now appears that
this maturation is maintained in adulthood. Adults
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displayed the greatest deﬁcits in working memory which
supports previous research which proposed that adults
with 22q11.2DS reach a “developmental plateau” in
working memory ability before controls, and so may not
experience ongoing age-appropriate increases in this
domain28. That study however did not extend beyond the
age of 26, whereas our wide age range up to 60 years old
provides insights into the relative strengths and weak-
nesses in adults with 22q11.2DS more generally, sug-
gesting that some domains such as processing speed may
“catch-up”, and others such as working memory may be
targets for remediation49. Executive performance has been
found to be associated with adaptive functioning in adults
with 22q11.2DS with or without schizophrenia, lending
support to the idea that remediation in executive perfor-
mance may also beneﬁt functional outcome18.
There were greater IQ impairments in adults with
22q11.2DS compared to younger individuals, as has been
previously reported12 which may be related to presence of
psychotic disorder (see above in Discussion section).
There were no differences between children and adoles-
cents with 22q11.2DS on IQ measures which contradicts
previous work that IQ deﬁcits are larger in adolescents
with 22q11.2DS than children6. The reason for this dis-
crepancy with previous ﬁndings may be a result of
including a control group, as previous longitudinal work
found that when taking into account control performance,
there was no strong evidence for a ‘cognitive decline’ over
childhood speciﬁc to 22q11.2DS24.
Limitations
The study was multi-site which facilitated a large sam-
ple size; furthermore, combining data from different sites
may reduce bias from individual sites50. However, as the
majority of the child and adolescent participants were
recruited from Cardiff University, and the majority of
adults from the other sites, it could be hypothesised that
differences between adults and the child and adolescent
group may be attributable to site speciﬁc characteristics
which inﬂuenced cognitive performance. However, add-
ing site as a covariate to the analyses generally did not
alter results, except there was a signiﬁcant difference
between children and adolescents on working memory
which was previously not signiﬁcant. Furthermore, it is a
strength that we have included adults, as there is far less
research on older individuals than paediatric 22q11.2DS
samples31.
Longitudinal studies have found that rates of psycho-
pathology such as ADHD and psychotic symptoms in
22q11.2DS have variable trajectories and may remit or
persist over time51,52. The cross-sectional design of the
current study was unable to capture this variation in the
same individuals over time and therefore associations
reported between cognition and psychopathology may
differ if measured longitudinally. Furthermore, comor-
bidity of psychopathology in 22q11.2DS may affect asso-
ciations between psychopathology and cognition.
Comorbidity is a common feature of 22q11.2DS51,53. It
could be argued that for the analysis of a speciﬁc trait,
possible overlap at the item level with another trait should
be taken into account. This would however, complicate
the interpretation of ﬁndings at the trait level and also
mean that the real-life complex clinical presentation of
these young people would no longer be adequately cap-
tured. Future studies of children with 22q11.2DS should
focus on dimensional measures of psychopathology that
capture symptoms that cut across traditional diagnostic
categories1.
Children with 22q11.2DS were younger on average than
child controls, however as the cognitive assessments took
age into account we would not expect this to impact
interpretation of results. Furthermore, although there
were signiﬁcantly more females in adult individuals with
22q11.2DS than controls running all analyses with gender
as a covariate did not change results. As some participants
were unable to complete the assessments, it’s possible that
our ﬁndings may not represent those individuals with the
greatest cognitive deﬁcits8.
Different versions of cognitive tests were used in older
and younger individuals, such as IQ tests, which is a
general issue in the ﬁeld6. Therefore it was important for
us to include comparison groups, to control for version
differences. However, the recruitment of adult sibling
controls is fraught with difﬁculty and therefore our adult
control sample consisted of individuals from the com-
munity. This may introduce bias as our comparisons for
child and adolescence groups consisted of family controls.
A meta-analysis reported that comparing the cognitive
performance of individuals with 22q11.2DS to community
controls produced smaller effect sizes than comparing
against control siblings31. However, this did not appear to
be the case in the current study, with effect sizes of a
similar magnitude across developmental stages.
This study made the most of the fact that several studies
had used the same measures. In future studies, best
practice would be for prospective assessment with the
same control recruitment strategy at several sites. Despite
this, in rare syndromes such as 22q11.2DS, it is best
practice to collaborate and data from different sites has
been pooled in many previous studies20,54.
Implications
The ﬁndings of the current study support the view that
it is essential to consider developmental period (child-
hood, adolescence, adulthood) when investigating cogni-
tive domains in individuals with 22q11.2DS as
observations generated when examining one develop-
mental stage may not apply to others. Furthermore,
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research linking cognition and psychopathology in
22q11.2DS, and indeed other genetic syndromes, should
account for developmental stages in their samples, as
grouping children and adolescents together in analyses
could mask potential associations. This study also shows
that it is important to investigate cognitive ability beyond
IQ as presence of ASD and ADHD was not associated
with IQ, but was with speciﬁc neurocognitive functions,
where the underlying mechanisms are more easily inter-
pretable than the general measure of IQ.
An especially important aim for future research is the
inclusion of more adults and older individuals with
22q11.2DS where there has been less research than on
paediatric populations. It is also important to include
comparison or control groups, which could take the form
of sibling, IQ-matched peers or typically developing peers,
as this enables interpretation of cognitive ﬁndings.
There is a need for increased awareness of clinicians of
critical periods or windows more amenable to interven-
tion which have been highlighted in this study, such as in
children with probable ASD, before greater impairment is
present in adolescence. Encouragingly, cognitive reme-
diation has been found to be feasible and effective in
adolescents with 22q11.2DS49, and may be especially
successful at these periods.
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